Medical diagnostics firm Werfen, along with its subsidiary Instrumentation Laboratory (IL), has acquired Warburg Pincus portfolio company Accriva Diagnostics.
Accriva produces point-of-care (POC) diagnostic products for coagulation and anti-platelet therapy response.
The firm’s product brands comprised of Hemochron POC coagulation systems, VerifyNow anti-platelet therapy response systems and AVOXimeter CO-Oximetry systems.
It also produces Tenderfoot, Tenderlett and Surgicutt incision products.
With around 460 employees, Accriva distributes its products to hospitals and critical care settings in around 90 countries.
Accriva Diagnostics, which will be operated under IL, will continue to run its existing San Diego facility.
Accriva Diagnostics president and CEO Scott Cramer said: "With our third consecutive year of record sales, significant operational efficiencies and new product pipeline, we foresee significant growth ahead.
“Now, the tremendous resources, expertise and global reach of Werfen and IL will accelerate this trajectory even further."
IL CEO Ramon Benet said: "The acquisition of Accriva strengthens our leadership in Hemostasis, Critical Care and Patient Blood Management testing.”
Based in Barcelona of Spain, Werfen develops and produces IVD testing solutions, while IL develops and manufactures in vitro diagnostic instruments, related reagents and data management solutions for use in hospitals and independent clinical laboratories.
Werfen’s other subsidiary firms include Inova Diagnostics that focuses on autoimmunity, Biokit that offers diagnostic reagents and clinical systems for infectious disease and other areas, and Systelab specializing in laboratory and hospital software solutions.